Is Sitagliptin a GLP-1?

Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Sitagliptin and glucagon-like peptide-1 (GLP-1) receptor agonists are often confused because both treat type 2 diabetes, but they belong to separate drug classes with distinct mechanisms of action. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that extends the activity of the body's natural incretin hormones, whereas GLP-1 agonists directly stimulate GLP-1 receptors throughout the body. This fundamental difference explains why GLP-1 drugs like semaglutide have emerged as powerful tools for weight management, while sitagliptin offers more modest metabolic effects.

What Is Sitagliptin and How Does It Work?

Sitagliptin, marketed under the brand name Januvia, belongs to a class of oral medications called DPP-4 inhibitors. These drugs work by blocking an enzyme (dipeptidyl peptidase-4) that normally breaks down two natural hormones called GIP and GLP-1 in the intestines. By slowing the breakdown of these hormones, sitagliptin allows them to remain active longer, which helps lower blood sugar levels after meals. The medication does not directly activate GLP-1 receptors; instead, it extends the lifespan of the body's own hormone signals.

Sitagliptin is taken orally once daily and is primarily used to improve glycemic control in type 2 diabetes patients. Clinical trials have shown that sitagliptin reduces hemoglobin A1c (a measure of average blood sugar over three months) by approximately 0.5 to 1.5 percentage points when used alone or in combination with other diabetes medications. Because it relies on the body's existing hormone pathways, sitagliptin is generally well-tolerated with a low risk of hypoglycemia (dangerously low blood sugar) when used alone.

GLP-1 Receptor Agonists: Direct Activation and Weight Loss

GLP-1 receptor agonists, such as semaglutide and tirzepatide, directly bind to and activate GLP-1 receptors located on brain cells, pancreatic cells, and throughout the gastrointestinal tract. Unlike sitagliptin, which allows the body to use its own limited supply of GLP-1, these medications deliver a synthetic or recombinant version of the hormone that provides a much stronger and more sustained signal. This direct activation produces multiple effects: it slows gastric emptying (the rate at which food leaves the stomach), increases feelings of fullness, reduces hunger signals in the brain, and improves insulin secretion in response to meals.

The potency of GLP-1 agonists translates into significant clinical benefits, particularly for weight loss. Large randomized controlled trials have demonstrated that patients taking semaglutide can expect weight reductions of 10 to 22 percent of their body weight over 68 weeks, compared to minimal weight change with placebo. Tirzepatide, which activates both GLP-1 and GIP receptors (a dual-action mechanism), has shown even more robust results, with some patients achieving weight loss exceeding 20 percent. These outcomes are substantially greater than what sitagliptin alone can deliver.

Key Differences Between Sitagliptin and GLP-1 Drugs

The fundamental difference between these drug classes lies in their pharmacology and clinical effects. Sitagliptin is a DPP-4 inhibitor that works indirectly by preserving the body's natural hormones, whereas GLP-1 agonists directly stimulate GLP-1 pathways with exogenous (externally supplied) medication. In terms of weight loss efficacy, GLP-1 drugs substantially outperform sitagliptin; while sitagliptin produces minimal weight change (often neutral or slight weight gain), semaglutide and tirzepatide consistently produce clinically meaningful weight reduction. Additionally, GLP-1 agonists have been shown to provide cardiovascular benefits in high-risk patients, including reduced heart attack and stroke risk, whereas sitagliptin's cardiovascular profile is neutral.

Route of administration also differs between these medications. Sitagliptin is taken orally as a tablet once daily, making it convenient for patients who prefer not to use injections. GLP-1 agonists are available in both injectable (once-weekly) and oral formulations, allowing flexibility based on patient preference and tolerability. PlexusDx offers compounded semaglutide injections starting at $149 per month, as well as oral semaglutide options, ensuring patients can select the delivery method that best fits their lifestyle while maintaining consistent pricing regardless of dose escalation.

Which Medication Is Right for Your Weight Loss Goals?

Choosing between sitagliptin and GLP-1 medications depends on individual health status, weight loss objectives, and tolerance for injection therapy. Patients whose primary goal is modest blood sugar control and who have minimal weight loss needs may benefit from sitagliptin as a first-line option; however, patients seeking significant, sustained weight reduction will find GLP-1 agonists substantially more effective. Because GLP-1 drugs address multiple metabolic pathways simultaneously—appetite regulation, glucose control, gastric motility, and even cardiovascular health—they represent a more comprehensive approach to metabolic transformation for many individuals.

Precision medicine further enhances the ability to select the optimal medication. PlexusDx offers the Precision Peptide Genetic Test, which analyzes key genetic variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 across 14 metabolic pathways and 150+ genetic insights. This testing helps identify individual peptide-pathway predispositions, allowing healthcare providers to predict which patients will respond most favorably to GLP-1 therapy versus alternative approaches. For those choosing semaglutide, PlexusDx provides access through licensed 503A compounding pharmacies across all 50 states, with no insurance requirement and HSA/FSA eligibility for convenient, affordable treatment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is sitagliptin a GLP-1 medication?

No, sitagliptin is not a GLP-1 medication. Sitagliptin is a DPP-4 inhibitor that works indirectly by extending the activity of the body's natural GLP-1 and GIP hormones, whereas GLP-1 agonists directly activate GLP-1 receptors with synthetic or recombinant hormone.

Why is semaglutide more effective for weight loss than sitagliptin?

Semaglutide directly activates GLP-1 receptors throughout the brain and gastrointestinal system with a much stronger signal than sitagliptin can provide. This produces profound appetite suppression, slowed gastric emptying, and enhanced satiety—leading to weight loss of 10 to 22 percent of body weight in clinical trials.

Can I switch from sitagliptin to a GLP-1 medication like semaglutide?

Yes, many patients successfully transition from DPP-4 inhibitors like sitagliptin to GLP-1 agonists under medical supervision. PlexusDx compounded semaglutide injections start at $149 per month through licensed 503A pharmacies in all 50 states, with no insurance required.

What are the side effects of GLP-1 drugs compared to sitagliptin?

Sitagliptin is generally very well-tolerated with minimal side effects and low hypoglycemia risk. GLP-1 agonists commonly cause gastrointestinal side effects—nausea, vomiting, diarrhea, and constipation—especially during dose escalation, though these typically diminish over time. GLP-1 drugs do not cause hypoglycemia when used alone.

How does the Precision Peptide Genetic Test help predict GLP-1 response?

PlexusDx's Precision Peptide Genetic Test analyzes 14 metabolic pathways and 150+ genetic insights, including variants in GLP1R, GIPR, FTO, and MC4R genes that influence individual responses to GLP-1 therapy.

Related Reading

• Maximus Glp 1
• Found Glp 1
• Orderly Meds Glp 1
• Henry Meds Glp 1

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.